How Plesha was paid
$4.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Other | Total |
|---|---|---|---|---|---|---|
| Scott M. PleshaChief Executive Officer | $219,802 | $240,900 | $1,129,653 | $2,557,650 | $5,163 | $4,153,168 |
| Francis Knuettel IIFormer Chief Financial Officer; Former Chief Executive Officer | $410,000 | $331,650 | $451,872 | $1,092,167 | $2,545 | $2,288,234 |
| Sai RangaraoChief Commercial Officer | $200,733 | $176,000 | $411,993 | $932,790 | $1,891 | $1,723,407 |
What changed and why
- $4.2M$4,153,168 was CEO Scott Plesha’s total compensation for 2025.
- $2.6M$2,557,650 was the CEO’s option-award compensation, alongside $1,129,653 in stock awards.
- 50%50% was the CEO’s target annual performance-based bonus under his employment agreement.
- $2.3M$2,288,234 was former CFO and CEO Francis Knuettel’s total 2025 compensation.
- $1.7M$1,723,407 was Chief Commercial Officer Sai Rangarao’s total 2025 compensation.
- July 1, 2025 marked the effective date of Plesha’s appointment as CEO and Rangarao’s appointment as Chief Commercial Officer.
Other Pelthos Therapeutics proxy statements
- 2025 proxy statement
Scott Plesha paid $0.
Filed Nov 25, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.